Stocks Retreat on New Development: Seagate Technology (NASDAQ:STX), Teva Pharmaceutical Industries (NYSE:TEVA)

Seagate Technology plc (NASDAQ:STX) [Trend Analysis] try to make new thrust in street and making different trends, stocks trading ended with -0.60% to $44.63. Seagate Planning to release a 16TB HDD Next Year, After releasing its 10TB BarraCuda Pro Hard Drive, last year as part of its Guardian Series that’s targeted at home use, Seagate is now planning to release a 16TB HDD next year.

The company is expected to launch its high-capacity hard disk drive within the next 18 months.The 16TB drive will be a standard 3.5-inch SATA drive and will be Helium-filled much like some of the other drives reported by Seagate itself and Western Digital in last two years, said in its report. Apart from the 16TB drive, the company is also testing a 12TB drive, the company’s CEO Stephen Luczo told

Luczo says that the initial response to the drive has been positive. The share price of STX attracts active investors, as stock price of week volatility recorded 5.05%. The stock is going forward to its 52-week low with 150.60% and lagging behind from its 52-week high price with -4.39%.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it -5.94% to close at $32.47 with the total traded volume of 9.08 Million shares. Israel’s Teva Pharmaceutical Industries has won U.S. approval to market a copy of GlaxoSmithKline’s best-selling Advair inhaler, although the real battle is still to come.

Teva’s version of GSK’s blockbuster medicine, called AirDuoRespiClick, is not directly substitutable for Advair and is only authorized for asthma, while Advair is also widely used for chronic obstructive pulmonary disease (COPD).Teva said on Monday it would launch AirDuo later this year. It has not said how much its product will cost. The firm has institutional ownership of 59.40%, while insider ownership included 2.70%. Its price to sales ratio ended at 1.69. TEVA attains analyst recommendation of 2.30 with week performance of 5.53%.


About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a Reply

Your email address will not be published. Required fields are marked *